Treatment of acute ischemic stroke part I: Recanalization strategies

Circulation

Volumn 106, Issue 12, 2002, Pages 1563-1569

  Broderick, Joseph P ^a   Hacke, Werner ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; FIBRINOLYTIC AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROUROKINASE; RETEPLASE; STREPTOKINASE; UROKINASE;

ACUTE HEART INFARCTION; ASPIRATION PNEUMONIA; BRAIN EDEMA; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DECUBITUS; DEEP VEIN THROMBOSIS; DRUG EFFECT; DRUG EFFICACY; FIBRINOLYTIC THERAPY; HUMAN; LUNG EMBOLISM; NEUROPROTECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECANALIZATION; RECURRENT DISEASE; REVIEW; SEIZURE; TREATMENT OUTCOME; URINARY TRACT INFECTION;

ACUTE DISEASE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; FIBRINOLYTIC AGENTS; HUMANS; INFUSIONS, INTRA-ARTERIAL; INFUSIONS, INTRAVENOUS; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS; STREPTOKINASE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0037126011     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000030406.47365.26     Document Type: Review

References (63)

1. Guidelines for the management of patients with acute ischemic stroke (AHA Medical/Scientific Statement)
2. Incidence rates of stroke and stroke subtypes among blacks
3. Ischemic stroke subtypes, a population-based study of functional outcome, survival, and recurrence
4. Incidence rates of first-ever ischemic stroke subtypes among blacks: A population-based study
5. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: A secondary analysis of the European-Australasian Acute Stroke Study (ECASS II)
6. Generalized efficacy of t-PA for acute stroke: Subgroup analysis of the NINDS t-PA Stroke Trial
7. Tissue plasminogen activator for acute ischemic stroke
8. Effect of rt-PA on ischemic stroke lesion size by computed tomography
9. A systems approach to immediate evaluation and management of hyperacute stroke: Experience at 8 centers and implications for community practice and patient care
10. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke
11. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke
12. The NINDS rt-PA Stroke Study: Sustained benefit at one year
13. Factors related to intracranial hematoma formation in patients receiving tissue-type plasminogen activator for acute ischemic stroke
14. Early stroke treatment associated with better outcome: The NINDS rt-PA stroke study
15. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke
16. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II): Second European-Australasian Acute Stroke Study Investigators
17. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset: The ATLANTIS Study: A randomized controlled trial: Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke
18. Dichotomized efficacy end points and global end-point analysis applied to the ECASS intention-to-treat data set: Post hoc analysis of ECASS I
19. Bootstrap statistics of ECASS II data: Just another post hoc analysis of a negative stroke trial?
20. Secondary analysis of ECASS data by time stratification: ECASS Study Group, European Cooperative Acute Stroke Study
21. Initial clinical experience with IV tissue plasminogen activator for acute ischemic stroke: A multicenter survey: The t-PA Stroke Survey Group
22. Effectiveness of t-PA in acute ischemic stroke: Outcome relates to appropriateness
23. Intravenous tissue plasminogen activator for acute ischemic stroke: Feasibility, safety, and efficacy in the first year of clinical practice
24. Use of tissue-type plasminogen activator for acute ischemic stroke: The Cleveland area experience
25. Lack of t-PA use for acute ischemic stroke in a community hospital: High incidence of exclusion criteria
26. Intravenous t-PA for acute ischemic stroke: Therapeutic yield of a stroke code system
27. Streptokinase for acute ischemic stroke with relationship to time to administration
28. Thrombolytic therapy with streptokinase in acute ischemic stroke
29. Randomized controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischemic stroke
30. Intra-arterial third-generation recombinant tissue plasminogen activator (reteplase) for acute ischemic stroke
31. Abciximab in acute ischemic stroke: A randomized, double-blind, placebo-controlled, dose-escalation study
32. Abciximab as an adjunct to high-risk carotid or vertebrobasilar angioplasty: Preliminary experience
33. Rescue treatment with abciximab in acute ischemic stroke
34. The clinical utility of intravenous integrilin combined with intra-arterial tissue plasminogen activator in acute ischemic stroke: The MGH experience
35. Apolipoprotein E phenotype and the efficacy of intravenous tissue plasminogen activator in acute ischemic stroke
36. The NINDS t-PA for Acute Stroke Protocol
37. Thrombolysis with intravenous rtPA in a series of 100 cases of acute carotid territory stroke: Determination of etiological, topographic, and radiological outcome factors
38. Pitfalls and potential of clinical diffusion-weighted MR imaging in acute stroke
39. Thrombolytic reversal of acute human cerebral ischemic injury shown by diffusion/perfusion magnetic resonance imaging
40. Expanding the window for thrombolytic therapy in acute stroke: The potential role of acute MRI for patient selection
41. Serial study of apparent diffusion coefficient and anisotropy in patients with acute stroke
42. Monitoring intravenous recombinant tissue plasminogen activator thrombolysis for acute ischemic stroke with diffusion and perfusion MRI
43. Diffusion, and perfusion-weighted MRI response to thrombolysis in stroke
44. Neuroradiologic evaluation of patients with acute stroke treated with recombinant tissue plasminogen activator
45. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke
46. Intravenous tissue plasminogen activator ameliorates the outcome of hyperacute embolic stroke
47. Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial
48. Combined intravenous and intraarterial recombinant tissue plasminogen activator in acute ischemic stroke
49. PROACT: A phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke
50. Intra-arterial prourokinase for acute ischemic stroke: The PROACT II study: A randomized controlled trial: PROlyse in Acute Cerebral Thromboembolism
51. Cerebral hemorrhage after intra-arterial thrombolysis
52. Outcome after local intra-arterial fibrinolysis compared with the natural course of patients with a dense middle cerebral artery, on early CT
53. Predictors of clinical improvement, angiographic recanalization, and intracranial hemorrhage after intra-arterial thrombolysis for acute ischemic stroke
54. Multicenter feasibility study of an ultrasound drug infusion microcatheter for treatment of acute ischemic stroke
55. Rheolytic thrombectomy of the occluded internal carotid artery in the setting of acute ischemic stroke
56. Angioplasty after intra-arterial thrombolysis for acute occlusion of intracranial arteries
57. Transcranial doppler ultrasound criteria for recanalization after thrombolysis for middle cerebral artery stroke
58. Ultra-early prediction of stroke outcome in patients treated with 0.9 mg/kg IV TPA
59. Guidelines for thrombolytic therapy for acute stroke: A supplement to the guidelines for the management of patients with acute ischemic stroke (AHA Medical/Scientific Statement)
60. Lack of clinical significance of early ischemic changes on computed tomography in acute stroke
61. ATLANTIS Trial: Results for patients treated within 3 hours of stroke onset
62. The rtPA (Alteplase) 0- to 6-hour acute stroke trial, part A (A0276g): Results of a double-blind, placebo-controlled, multicenter study